



Updates to the Medi-Cal Rx Provider Manual

July 1, 2022

The updates/additions below have been made to the *Medi-Cal Rx Provider Manual*.

For more information, see the [Medi-Cal Rx Provider Manual](#) Version 1.15 on the Medi-Cal Rx Web Portal.

| Section | Update Description | Effective Date |
|--|--|----------------|
| <i>Section 4.6.2 – Professional Dispensing Fee</i> | Added the following verbiage: “Unless noted otherwise below,” | July 1, 2022 |
| <i>Section 4.6.13 – Medical Supply Reimbursement</i> | Added the following verbiage under Upper Billing Limit: <ul style="list-style-type: none">• “minus a 10 percent payment reduction for the following products:<ul style="list-style-type: none">– Alcohol Prep Pads, Heparin and Normal Saline Flush solutions, Diaphragms and Cervical Caps, Condoms, Pen Needles, Peak Flow Meters and Inhaler Assist Devices, Sterile Syringes with Needles, and Miscellaneous Medical Supplies.• The MAPC price on file for the item plus the appropriate professional dispense fee minus a 10 percent payment reduction for the following products:<ul style="list-style-type: none">– Diabetic Test Strips, Lancets, NDC-Billed Self-Monitoring Blood | July 1, 2022 |

| Section | Update Description | Effective Date |
|---|--|----------------|
| | Glucose Systems, Control Solutions, Lancing Devices, Disposable Insulin Delivery Devices, Therapeutic Continuous Glucose Monitoring (CGM) Systems, and Insulin Syringes." | |
| <i>Section 4.6.14 – Enteral Nutrition Products Reimbursement</i> | Added the following verbiage: "minus a 10 percent reduction (W&I Code, Section 14105.192)." | July 1, 2022 |
| <i>Section 12.3.5 – Specialty Infant Products Criteria</i> | <ul style="list-style-type: none"> • Updated verbiage "Authorization for specialty infant products is limited to a maximum <i>two</i>-month term..." to "Authorization for specialty infant products is limited to a maximum <i>four</i>-month term..." • Deleted this sentence: <ul style="list-style-type: none"> – "During the Medi-Cal Rx transition, starting January 1, 2022, authorization limitation is expanded to a maximum 4-month term. A 60-day notice will be published, announcing when the limitation will revert back to a maximum 2-month term, except when noted" | July 1, 2022 |
| <i>Section 17.0 – COVID-19 Vaccine Coverage, Reimbursement, and OTC Antigen Test Kits</i> | Added additional NDC for adult beneficiaries in Table 17.0-1 and 17.0-3 <ul style="list-style-type: none"> • NDC: 80777010099 Spikevax (COVID-19 Vaccine, mRNA) | July 1, 2022 |
| <i>Section 17.1 – Pediatric COVID-19 Vaccine Coverage</i> | Added the following verbiage: "Effective for dates of service <i>on or after</i> May 17, 2022, the FDA amended the EUA for the use of the Pfizer-BioNTech COVID-19 Vaccine to include a booster dose for | July 1, 2022 |

| Section | Update Description | Effective Date |
|---|---|---------------------|
| | <p>children aged 5 through 11 years. Like the adult dose, children will need a booster dose of the Pfizer-BioNTech COVID-19 Vaccine at least 5 months after completion of a primary series of COVID-19 vaccine administrations.”</p> | |
| <p><i>Section 20.0 – Drug and Product Shortages</i></p> | <ul style="list-style-type: none"> • Updated verbiage “For enteral nutrition products through July 1, 2022, substitution has been allowed without the need for a new prescription from the prescriber.” to “For enteral nutrition products, substitution has been temporarily... ” • Added the following verbiage: <ul style="list-style-type: none"> – “This policy will remain in place until the national supply of infant formulary stabilizes. Prior to the Department removing this substitution without a PA policy in the future, a 90-day notice will be published, allowing substantial notification to providers and stakeholders.” • Added the following linked reference: <ul style="list-style-type: none"> – “Enteral Nutrition Update: Interchange of Equivalent Contracted Enteral Nutrition Product and Specialty Infant Authorization Term Limit” | <p>July 1, 2022</p> |